Education & Events

Follow us on our journey to develop a paradigm shift in the treatment of autoimmune diseases.

Featured             

inside-kyverna-team

Watch Time: 04:45
Learn more about KYSA-1, an open-label, Phase 1/2 clinical trial of KYV-101, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy

Key Publications

Anti-CD19 CAR T cells for refractory myasthenia gravis

Haghikia A, et al.

Lancet Neurology 2023;22:P1104-1105

CAR T-cell therapy in autoimmune diseases

Schett G, et al.

Lancet 2023;402:2034-2044

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

Mackensen A, et al.

Nat Med 2022;28:2424-2132

Meet Kyverna

June 12 – 15, 2024

Vienna, Austria

The European Congress of Rheumatology provides a forum of the highest standard for scientific (both clinical and basic), educational, and social exchange between professionals involved in rheumatology, liaising with patient organizations, in order to achieve progress in the clinical care of people with rheumatic diseases.

June 29 – July 2, 2024

Helsinki, Finland

This year’s overarching theme is ‘Neuromodulation: advances and opportunities in neurological diseases’ and there will be a range of workshops and plenary sessions addressing this subject. Leading specialists will tackle hot topics in invasive and non-invasive neuromodulation in movement and cognitive disorders, chronic pain, and refractory epilepsy.

September 18 - 20, 2024

Copenhagen, Denmark

ECTRIMS 2024 is the premier meeting place for researchers, clinicians, and healthcare providers to collaborate on the next life-changing research and treatment options for people with MS and related diseases.

Educational Videos

Watch Time: 05:01

Learn about current management of lupus nephritis and how current clinical trials are evaluating novel therapeutic approaches to address unmet needs in the treatment of lupus nephritis.

Watch Time: 09:45

Learn more about the current strategies for the management of lupus nephritis, from meticulous control of blood pressure, inflammation, to ensure that comprehensive care is kept in the picture to account for patient lifestyle and preference.

Stay up-to-date

Follow our journey to develop a paradigm shift in the treatment of autoimmune diseases.